Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8616810 | 0.85 | HSPB1 (0.51) | HSPB1ALDH1A1HIF1AMAPTMAPK1 | |
| SCHEMBL5578046 | 0.82 | HTT (0.53) | ALDH1A1HIF1AL3MBTL1MAPTMAPK1 | |
| SCHEMBL8756394 | 0.81 | HSPB1 (0.49) | HSPB1ALDH1A1HIF1AS1PR4L3MBTL1 | |
| SCHEMBL27792279 | 0.80 | HSPB1 (0.48) | HSPB1ALDH1A1HIF1AS1PR4L3MBTL1 | |
| SCHEMBL6268161 | 0.80 | PDE4A (0.39) | HSPB1ALDH1A1HIF1AMAPTMAPK1 | |
| SCHEMBL8772712 | 0.78 | KMT2A (0.39) | HSPB1ALDH1A1L3MBTL1MAPTPDE4A | |
| SCHEMBL8643566 | 0.78 | HSPB1 (0.51) | HSPB1ALDH1A1HIF1AS1PR4L3MBTL1 | |
| SCHEMBL6686530 | 0.77 | POLB (0.45) | ALDH1A1L3MBTL1MAPTMAPK1LMNA | |
| SCHEMBL31305332 | 0.77 | EPAS1 (0.50) | HSPB1L3MBTL1TDP1 | |
| SCHEMBL37687 | 0.77 | CA1 (0.62) | HSPB1ALDH1A1MAPTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170863-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2018-06-21 | — | — | US | disclosed |
| US-8614229-B2 | Substituted indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| WO-2013171729-A2 | ARYL AND HETEROARYL AMIDE COMPOUNDS AS RORGAMAT MODULATOR | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-11-21 | — | — | WO | disclosed |
| EP-2197842-B1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORP (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2408761-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| EP-2197842-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-2197884-A2 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032123-A2 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | HSPB1 3971/4885ALDH1A1 2482/4885HIF1A 1852/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | HSPB1 3567/4885ALDH1A1 1792/4885HIF1A 806/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | HSPB1 4032/4885ALDH1A1 800/4885HIF1A 1101/4885 |
| US-20180170863-A1 | ROR GAMMA (RORY) MODULATORS | RORB, RORA, RORC | HSPB1 2052/4885ALDH1A1 687/4885HIF1A 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.